Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial
- Authors
- Kim, Chee Hae; Han, Kyung Ah; Yu, Jaemyung; Lee, Sang Hak; Jeon, Hui Kyung; Kim, Sang Hyun; Kim, Seok Yeon; Han, Ki Hoon; Won, Kyungheon; Kim, Dong-Bin; Lee, Kwang-Jae; Min, Kyungwan; Byun, Dong Won; Lim, Sang-Wook; Ahn, Chul Woo; Kim, SeongHwan; Hong, Young Joon; Sung, Jidong; Hur, Seung-Ho; Hong, Soon Jun; Lim, Hong-Seok; Park, Le Byung; Kim, In Joo; Lee, Hyoungwoo; Kim, Hyo-Soo
- Issue Date
- Jan-2018
- Publisher
- ELSEVIER
- Keywords
- combination; hypertriglyceridemia; non-HDL-C; omega-3 fatty acids; rosuvastatin; triglycerides
- Citation
- CLINICAL THERAPEUTICS, v.40, no.1, pp.83 - 94
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL THERAPEUTICS
- Volume
- 40
- Number
- 1
- Start Page
- 83
- End Page
- 94
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/78455
- DOI
- 10.1016/j.clinthera.2017.11.007
- ISSN
- 0149-2918
- Abstract
- Purpose: The purpose of this study was to examine the efficacy and safety of adding omega-3 fatty acids to rosuvastatin in patients with residual hypertriglyceridemia despite statin treatment. Methods: This study was a multicenter, randomized, double-blind, placebo-controlled study. After a 4-week run-in period of rosuvastatin treatment, the patients who had residual hypertriglyceridemia were randomized to receive rosuvastatin 20 mg/d plus omega-3 fatty acids 4 g/d (ROSUMEGA group) or rosuvastatin 20 mg/d (rosuvastatin group) with a 1:1 ratio and were prescribed each medication for 8 weeks. Findings: A total of 201 patients were analyzed (mean [SD] age, 58.1 [10.7] years; 62.7% male). After 8 weeks of treatment, the percentage change from baseline in triglycerides (TGs) and non-HDL-C was significantly greater in the ROSUMEGA group than in the rosuvastatin group (TGs: -26.3% vs -11.4%, P < 0.001; non-HDL-C: -10.7% vs -2.2%, P = 0.001). In the linear regression analysis, the lipid-lowering effect of omega-3 fatty acids was greater when baseline TG or non-HDL-C levels were high and body mass index was low. The incidence of adverse events was not significantly different between the 2 groups. (C) 2018 The Authors. Published by Elsevier HS Journals, Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/78455)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.